Introduction
Neurology sits at one of medicine’s most challenging frontiers. The brain’s complexity, its relative inaccessibility, and the difficulty of measuring neurological improvement with regulatory-grade precision have made CNS drug development uniquely demanding. Alzheimer’s disease, after decades of high-profile failures, is cautiously entering a new era of biological plausibility. CIDP is seeing rigorous Phase 3 investigation. Neurovascular imaging technology is advancing with precision that may transform how physicians treat brain aneurysms in real time. Recent milestones across all three deserve careful attention.
Annovis Bio Advances Into Pivotal Alzheimer’s Phase 3
Alzheimer’s drug development has produced some of the most visible failures in pharmaceutical history. The recent approvals of amyloid-targeting therapies have shifted the scientific consensus — such approaches can produce meaningful effects on disease trajectory — but the field continues searching for therapies with better safety profiles, broader mechanisms, and greater accessibility.
Annovis Bio’s advancement of buntanetap into a pivotal Phase 3 reflects confidence in earlier-stage data. Buntanetap is designed to inhibit the translation of multiple neurotoxic proteins — not only amyloid precursor protein but also tau, alpha-synuclein, and TDP-43. This multi-target approach reflects a mechanistic bet that Alzheimer’s pathology is more complex than the amyloid cascade hypothesis alone suggests, and that simultaneously reducing multiple toxic proteins may outperform single-target amyloid therapy.
Halneuron Phase 2b Reaches the 50% Enrollment Milestone
The Halneuron Phase 2b trial has achieved 50% enrollment — a milestone that carries more operational significance than it might initially appear. Mid-stage enrollment is often where clinical programs stall, as initial site qualification and patient identification give way to the harder work of identifying and consenting participants who meet all eligibility criteria. Reaching 50% on schedule signals strong operational execution and provides confidence the study will reach full accrual within projected timelines.
Dianthus Navigates CIDP Phase 3 with Adaptive Precision
Chronic inflammatory demyelinating polyneuropathy is an autoimmune disorder in which the immune system attacks peripheral nerve myelin, causing progressive weakness and sensory disturbance. Standard of care — intravenous immunoglobulin, corticosteroids, plasmapheresis — is effective for many patients but involves chronic administration and incomplete response for a meaningful proportion.
Dianthus Therapeutics is using CAPTIVATE Phase 3 interim data not as a stop/go decision, but as an opportunity to refine enrollment criteria, validate responder definitions, and optimize the remaining trial phases based on what has been learned from initial patients. In a disease as heterogeneous as CIDP, this adaptive approach reflects genuine understanding of the condition’s clinical complexity.
Spryte Medical Brings Real-Time OCT to Neurovascular Procedures
Treatment of intracranial aneurysms typically relies on fluoroscopic imaging to guide catheter placement during endovascular intervention — a two-dimensional approach to a three-dimensional anatomical problem, with limited visualization of vessel wall–device interactions.
Spryte Medical’s InSyte system, now in an FDA-approved clinical trial following enrollment of its first participants, applies intravascular optical coherence tomography to neurovascular procedures. Originally developed in coronary cardiology, OCT provides real-time cross-sectional visualization of vessel wall anatomy and device-tissue interactions at resolutions fluoroscopy cannot approach. In aneurysm treatment — where precision of coil or device placement directly affects procedural success and recurrence risk — this level of visualization could meaningfully improve outcomes for patients undergoing complex endovascular procedures.
For ongoing updates on CNS and neurological clinical trial developments, visit clinical trial vanguard’s neurology and neurovascular research coverage
Conclusion
The neurology pipeline reflects both the field’s extraordinary difficulty and its genuine momentum. Annovis’s Phase 3 commitment in Alzheimer’s, Halneuron’s enrollment milestone, Dianthus’s adaptive CIDP strategy, and Spryte Medical’s neurovascular imaging trial each represent meaningful advances in a space that has historically offered more disappointment than progress. The next generation of neurological therapies is being built — carefully, rigorously, and with hard-won knowledge of what has failed before.